Brief: Imac Holdings Announces Completion Of Third Cohort Of Its Phase 1 Clinical Study Of Umbilical Cord-Derived Mesenchymal Stem Cells
09/09/2022 14:25
Sept 9 (Reuters) - IMAC Holdings Inc BACK.O :
* IMAC HOLDINGS, INC. ANNOUNCES COMPLETION OF THIRD COHORT
OF ITS
PHASE 1 CLINICAL STUDY OF UMBILICAL CORD-DERIVED MESENCHYMAL
STEM CELLS FOR TREATMENT OF BRADYKINESIA DUE TO PARKINSON'S
DISEASE
Source text for Eikon: ID:nGNX2j5Sl9
Further company coverage: BACK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imac Holdings
See all newsBrief: Nasdaq To Suspend Imac Holdings Stock Trading On March 26, 2025
Imac Holdings Inc Reports Results For The Quarter Ended September 30: Earnings Summary
Brief: Imac Holdings Inc - Regains Compliance With Nasdaq Audit Committee Rule
Imac Holdings Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Brief: IMAC Holdings Enters Agreement To Issue 4,676 Shares Of Series G Preferred Stock